Formula food for special medical purpose as well as preparation method and application of formula food

Abstract

The present invention provides a special medical use formula food and a preparation method and application thereof, the special medical use formula food contains DHA, ARA and nervonic acid composition, the mass ratio of DHA to ARA is 0.2-5: 1, and the mass ratio of the total amount of DHA and ARA to nervonic acid is 0.8-20: 1; wherein the protein content is 10-16 g / 100 g, the fat content is 21-32 g / 100 g, and the carbohydrate content is 50-58 g / 100 g according to the dry matter mass of the formula food for the special medical purpose, and the formula food for the special medical purpose has the effect of effectively improving and / or improving individual social behaviors.

Description

Technical Field

[0001] The present invention relates to the technical field of functional nutrient research, and in particular to a special medical formula food and a preparation method and application thereof. Background Art

[0002] The early stage of life is the fastest period of body development, and the childhood stage is the golden period of healthy development throughout the entire life stage. It is very important to ensure the stable and healthy development of children. Balanced nutrition has the most important impact on healthy development. DHA (docosahexaenoic acid), ARA (arachidonic acid) and neuraminic acid are three important polyunsaturated fatty acids. DHA is a fatty acid that is mainly found in the brain, nerve tissue and retina. It not only constitutes an important component of these tissues, but also helps to maintain the fluidity and stability of cell membranes. ARA is also an important fatty acid in the brain and participates in the structure and function of nerve cells. As a special fatty acid, neuraminic acid is an important component of brain white matter and is indispensable for the health and development of the nervous system. In the current existing technology, DHA, ARA and neuraminic acid are usually added alone or in combination to infant or children's formula or nutritional products to enhance their nutritional functional value. However, the current effects of DHA, ARA and neuraminic acid on brain function are mostly focused on the effects of single components, while there are relatively few studies on the combined effects of these components. In addition, there is still a lack of in-depth research on how to optimize the proportion and method of adding these components to achieve the best nutritional effect.

[0003] Social behavior refers to an individual's ability to interact with people around him and to take care of himself, and is included in the evaluation dimensions of WS / T 580-2017 "Developmental Behavior Assessment Scale for Children Aged 0 to 6". Early childhood is a sensitive and critical period for the development of individual social behavior. The development of good social behavior has a long-term impact on the healthy growth and socialization process of children, and is of great significance to the development of other individual adaptability.

[0004] After searching, there are few reports in the prior art on whether diet affects individual social behavior and what kind of impact it has on individual social behavior. Summary of the invention

[0005] In order to solve the above technical problems, the purpose of the present invention is to provide a special medical purpose formula food and its preparation method and application, which contains DHA, ARA and neuraminic acid composition, and has the effect of effectively enhancing and / or improving individual social behavior.

[0006] To achieve the above object, the present invention first provides a special medical purpose formula food, which contains DHA, ARA and neuraminic acid composition, wherein the mass ratio of DHA to ARA is 0.2-5:1, and the mass ratio of the total amount of DHA and ARA to neuraminic acid is 0.8-20:1;

[0007] Among them, based on the dry matter weight of the special medical purpose formula food, the protein content is 10-16g / 100g, the fat content is 21-32g / 100g, and the carbohydrate content is 50-58g / 100g. The special medical purpose formula food is selected from one or more of the following: lactose-free formula or low-lactose formula food for infants, partially hydrolyzed milk protein formula food for infants, deeply hydrolyzed milk protein formula food for infants, amino acid formula food for infants, formula food for premature / low birth weight infants, breast milk nutritional supplements, formula food for infant amino acid metabolism disorders, complete nutrition formula food for food protein allergy, complete nutrition formula food for inflammatory bowel disease, complete nutrition formula food for gastrointestinal absorption disorders, and complete nutrition formula food for abnormal fatty acid metabolism.

[0008] According to a specific embodiment of the present invention, in the special medical purpose formula food of the present invention, the mass ratio of DHA to ARA is 0.3-3:1, and the mass ratio of the total amount of DHA and ARA to neuraminic acid is 0.8-20:1.

[0009] According to some specific embodiments of the present invention, in the special medical purpose formula food of the present invention, the mass ratio of DHA to ARA is preferably 0.5-2.5:1.

[0010] According to some specific embodiments of the present invention, in the special medical purpose formula food of the present invention, the mass ratio of DHA to ARA is preferably 0.5-2:1.

[0011] According to some specific embodiments of the present invention, in the special medical purpose formula food of the present invention, the mass ratio of DHA to ARA is preferably 0.5-1.5:1, for example 0.5:1, 0.6:1, 0.67:1, 0.8:1, 1:1, 1.1:1, 1.2:1, 1.3:1 or 1.4:1.

[0012] According to some specific embodiments of the present invention, in the special medical purpose formula food of the present invention, the mass ratio of the total amount of DHA and ARA to neuraminic acid is 0.8-10:1.

[0013] According to some specific embodiments of the present invention, in the special medical purpose formula food of the present invention, the mass ratio of the total amount of DHA and ARA to neuraminic acid is 0.8-8:1.

[0014] According to some preferred specific embodiments of the present invention, in the special medical purpose formula food of the present invention, the mass ratio of the total amount of DHA and ARA to neuraminic acid is 0.8-5:1, further preferably 0.8-3:1, for example 0.9:1, 1:1, 1.1:1, 1.2:1, 1.3:1, 1.5:1, 2:1, 2.5:1 or 3:1.

[0015] According to some specific embodiments of the present invention, in the special medical purpose formula food of the present invention, the mass ratio of the total amount of DHA and ARA to neuraminic acid is 10-20:1, for example, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1 or 20:1.

[0016] In the above-mentioned special medical purpose formula food, the raw material for providing the DHA can be DHA oil and / or powder derived from one or a combination of two or more of algae, tuna oil, fish oil, milk-derived DHA from feed nutrition regulation and biotransformation, egg yolk extract and krill oil; wherein the algae can be one or a combination of two or more of Schizochytrium, Okenichthys and Crypthecodinium. Unless otherwise specified, the ratio of DHA to other functional components in the special medical purpose formula food of the present invention is based on the content of DHA in the raw material.

[0017] In the above-mentioned special medical purpose formula food, the raw material for providing the ARA can be one or more raw materials derived from algae and other oils containing ARA. Unless otherwise specified, the ratio of the ARA to other functional components in the special medical purpose formula food of the present invention is based on the content of ARA in the raw material.

[0018] In the above-mentioned special medical purpose formula food, the raw material for providing the nervonic acid can be one or a combination of two or more of nervonic acid derived from cis-15-tetracosenoic acid, Acer truncatum seed oil, nervonic acid synthesized by microbial fermentation, and other oils containing nervonic acid. Unless otherwise specified, the ratio of the nervonic acid to other functional components in the special medical purpose formula food of the present invention is based on the content of nervonic acid in the raw material.

[0019] According to a specific embodiment of the present invention, in the special medical purpose formula food of the present invention, the amount of ARA contained in the food is 10-420 mg / 100 g of food dry matter, calculated based on the amount of ARA in the composition.

[0020] According to some specific embodiments of the present invention, in the special medical purpose formula food of the present invention, based on the amount of ARA in the composition, the amount of ARA contained in the food is 10-200mg / 100g food dry matter. According to some more specific embodiments of the present invention, in the special medical purpose formula food of the present invention, based on the amount of ARA in the composition, the amount of ARA contained in the food is about 30, about 60mg / 100g food dry matter, about 65mg / 100g food dry matter, about 85mg / 100g food dry matter, about 120mg / 100g food dry matter, about 150mg / 100g food dry matter.

[0021] According to some specific embodiments of the present invention, in the special medical purpose formula food of the present invention, the amount of ARA contained in the food is 15-400 mg / 100 g of food dry matter, calculated based on the amount of ARA in the composition.

[0022] In some specific embodiments of the present invention, in the special medical purpose formula food of the present invention, the amount of ARA contained in the food is 20-150 mg / 100 g food dry matter, 100-200 mg / 100 g food dry matter, 200-300 mg / 100 g food dry matter or 300-400 mg / 100 g food dry matter, calculated on the amount of ARA in the composition.

[0023] In some specific embodiments of the present invention, the content of DHA and neuraminic acid in the special medical purpose formula food of the present invention can be determined according to the ratio with ARA.

[0024] In the above-mentioned special medical purpose formula food, preferably, the amount of ARA contained in the special medical purpose formula food is 10-420 mg / 100 g of food dry matter, calculated based on the amount of DHA, ARA and ARA in the neuraminic acid composition. Preferably, the amount of ARA contained in the special medical purpose formula food is 15-400 mg / 100 g of food dry matter.

[0025] According to a specific embodiment of the present invention, in the special medical purpose formula food described in the present invention, the raw material for providing fat includes vegetable oil in addition to the basic raw material containing milk fat, and the vegetable oil may include but is not limited to one or more of sunflower oil, corn oil, soybean oil, rapeseed oil, coconut oil, palm oil, walnut oil, and maple seed oil, preferably including sunflower oil, corn oil, maple seed oil and soybean oil. The addition of these vegetable oils provides fat components for the product on the one hand, and linoleic acid and α-linolenic acid on the other hand, and can also provide nervonic acid. The content of nervonic acid in maple seed oil is usually between 5% and 10%. In addition, the raw material for providing fat can also selectively include medium-chain triglycerides, and raw material OPO structured fat added to provide 1,3-dioleyl-2-palmitoyl triglyceride. Since the purity of the OPO structural fat raw materials currently sold on the market is different, that is, the content of the effective ingredient 1,3-dioleyl-2-palmityl triglyceride is different, usually around 40% to 70%, in the present invention, in order to distinguish the effective ingredient 1,3-dioleyl-2-palmityl triglyceride and its raw materials, the term "1,3-dioleyl-2-palmityl triglyceride" is used when describing the effective ingredient, and the commonly known "OPO structural fat" is used when describing the food raw materials providing the effective ingredient 1,3-dioleyl-2-palmityl triglyceride. The specific addition amount of OPO structural fat can be converted according to the content requirements of 1,3-dioleyl-2-palmityl triglyceride in the milk powder product of the present invention and the purity of the OPO structural fat raw material. More preferably, based on 1000 parts by weight of the special medical purpose formula food of the present invention, its raw materials include but are not limited to: 5 to 100 parts by weight of Acer truncatum seed oil; 0 to 150 parts by weight of sunflower seed oil; 0 to 50 parts by weight of corn oil; 0 to 80 parts by weight of soybean oil; 0 to 100 parts by weight of low-erucic acid rapeseed oil; 0-150 parts by weight of medium-chain triglycerides; and 0 to 140 parts by weight of OPO structured fat.

[0026] According to a specific embodiment of the present invention, in the special medical formula food of the present invention, carbohydrates come from lactose or non-lactose sources, including but not limited to pregelatinized starch, maltodextrin, solid corn syrup, glucose syrup, and some come from modified starch emulsifiers. That is, in the special medical formula food of the present invention, the raw materials for providing carbohydrates, in addition to the basic raw materials containing lactose, also include but are not limited to raw lactose, emulsifiers and pre-hydrolyzed or gelatinized starch substances. Preferably, based on 1000 parts by weight of the special medical formula food, its raw materials include but are not limited to: 0 to 580 parts by weight of lactose, and 0-580 parts by weight of non-lactose substances. The specific amount of lactose added can be adjusted within the range so that the carbohydrate content of the present invention is 50 to 58g / 100g.

[0027] According to a specific embodiment of the present invention, the raw materials of the special medical formula food of the present invention further include but are not limited to one or more of appropriate DHA, ARA, EPA, nucleotides, lactoferrin, etc., and also include compound nutrients including calcium powder, vitamins and minerals. Preferably, based on 1000 parts by weight of the special medical formula food of the present invention, the raw materials include: 1-20 parts by weight of DHA, 2-30 parts by weight of ARA; 10-140 parts by weight of EPA; 7-70 parts by weight of compound nutrients including calcium powder, vitamins and minerals.

[0028] More preferably, the special medical purpose formula food is a partially hydrolyzed infant milk protein formula food or an extensively hydrolyzed infant milk protein formula food; the total protein in the partially hydrolyzed infant milk protein formula food includes hydrolyzed milk protein, and the protein with a molecular weight distribution of less than 1000 dal accounts for more than 30% of the total protein, usually less than 70%, preferably more than 40%, usually less than 70%; the total protein in the extensively hydrolyzed infant milk protein formula food includes hydrolyzed milk protein, and the protein with a molecular weight distribution of less than 1000 dal accounts for more than 70% of the total protein, preferably more than 80%.

[0029] Further preferably, based on 1000 parts by weight of the partially hydrolyzed infant milk protein formula, the raw materials include:

[0030]

[0031] It is understood that the specific amount of each raw material in the special medical purpose formula food of the present invention should be adjusted and determined on the premise of meeting the requirements of the formula milk powder product index. In the special medical purpose formula food of the present invention, the product performance indicators not described or listed in detail should be implemented in accordance with the standards of infant formula food or modulated milk powder and relevant standards and regulations.

[0032] In a special medical purpose formula food of the present invention, each raw material can be commercially available, and the selection of each raw material should comply with the requirements of relevant standards. In addition, the compounded nutrients can also be compounded by themselves. In the present invention, "compounding" is used only for the convenience of expression, and it does not mean that the components in the compound must be mixed together before use. Each raw material should be added and used under the premise of meeting relevant laws and regulations.

[0033] Further preferably, based on 1000 parts by weight of the infant milk protein extensively hydrolyzed formula food, the raw materials include:

[0034]

[0035] It is understood that the specific amount of each raw material in the special medical purpose formula food of the present invention should be adjusted and determined on the premise of meeting the product index requirements of the formula milk powder. In the special medical purpose formula food of the present invention, the product performance indicators not described or listed in detail should be implemented in accordance with the standards of infant formula food or modulated milk powder and relevant standards and regulations.

[0036] In a special medical purpose formula food of the present invention, each raw material can be commercially available, and the selection of each raw material should comply with the requirements of relevant standards. In addition, the compounded nutrients can also be compounded by themselves. In the present invention, "compounding" is used only for the convenience of expression, and it does not mean that the components in the compound must be mixed together before use. Each raw material should be added and used under the premise of meeting relevant laws and regulations.

[0037] In the special medical purpose formula food of the present invention, the compound nutrients are a combination of nutrients that meet the standards, and different addition amounts are used according to different formulas. The formula milk powder of the present invention can selectively use any one or any combination of the following compound nutrient ingredients if nutrients are added as needed. In the above-mentioned special medical purpose formula food, preferably, the amount of each component of the compound nutrients containing calcium powder, vitamins and minerals is:

[0038] Component 1: complex vitamins, wherein each gram of complex vitamins contains:

[0039] Taurine: 25-340 mg;

[0040] Vitamin A: 1700~5800μgRE;

[0041] Vitamin D: 25-70 μg;

[0042] Vitamin B1: 2000~6800μg;

[0043] Vitamin B2: 3000~6900μg;

[0044] Vitamin B6: 1700-4000 μg;

[0045] Vitamin B 12 : 8~20μg;

[0046] Vitamin K1: 200-700 μg;

[0047] Vitamin C: 0-700 mg;

[0048] Vitamin E: 10-70 mg α-TE;

[0049] Nicotinamide: 10000~41550μg;

[0050] Folic acid: 350-920 μg;

[0051] Biotin: 70-245 μg;

[0052] Pantothenic acid: 7100-25230 μg;

[0053] Inositol: 0-250mg;

[0054] L-Carnitine: 0-60mg;

[0055] Component 2: Mineral II, wherein each gram of Mineral II contains:

[0056] Sodium: 40-100 mg;

[0057] Potassium: 200-500 mg;

[0058] Component 3: Mineral Three, of which each gram of Mineral Two:

[0059] Calcium: 200-500 mg;

[0060] Phosphorus: 75-300 mg;

[0061] Component 4: Mineral 1, wherein per gram of Mineral 1:

[0062] Iron: 20-110 mg;

[0063] Zinc: 23-90 mg;

[0064] Copper: 2000-4180 μg;

[0065] Iodine: 500-995 μg;

[0066] Selenium: 0-200 μg;

[0067] Manganese: 0-579 μg;

[0068] Component 5: Compound magnesium chloride, wherein per gram of magnesium chloride:

[0069] Magnesium: 80-170 mg;

[0070] Component 6: Choline chloride, wherein per gram of choline chloride:

[0071] Choline: 200-950 mg.

[0072] The base material of the above-mentioned compound nutrient containing calcium powder, vitamins and minerals is preferably lactose, solid corn syrup or L-sodium ascorbate. Based on 1000 parts by weight of the special medical formula food, the addition amount of the compound nutrient containing calcium powder, vitamins and minerals is 7 to 70 parts by weight, wherein component 1 is preferably 2 to 8 parts by weight, component 2 is preferably 2 to 40 parts by weight, component 3 is preferably 0.5 to 40 parts by weight, component 4 is preferably 0.5 to 6 parts by weight, component 5 is 0 to 7 parts by weight, and component 6 is 0 to 3 parts by weight, and the base material of each component is preferably maltodextrin or L-sodium ascorbate.

[0073] The compound raw materials used to provide each nutrient in each component may interact with each other. For example, sulfate can accelerate the oxidation and destruction of vitamins, reducing their utilization rate. Because sulfate appears in the form of ions in aqueous solution, it acts as an oxidant in the oxidation reaction to induce the oxidation of vitamins and destroy the structure of vitamins. Trace elements have different abilities in redox reactions, with copper, zinc and iron being the most active, followed by manganese and selenium. B vitamins and vitamin C are easily affected by copper ions, while vitamin B2 is easily affected by iron ions.

[0074] In order to ensure the utilization efficiency of nutrient substances, the present invention selects a stable nutrient dosage form, for example: vitamin A uses retinyl acetate. Retinol contains 1 hydroxyl group and 5 double bonds and is very easy to oxidize, but the stability of retinol in the form of acetate is greatly improved; vitamin E uses tocopherol acetate. Tocopherol is also very unstable, but the stability of tocopherol acetate is greatly improved; vitamin B1 uses thiamine nitrate. Among the existing forms of thiamine, thiamine nitrate is more stable than thiamine hydrochloride; vitamin C uses sodium L-ascorbate.

[0075] The content of each component of the above-mentioned compound nutrients including calcium powder, vitamins and minerals refers to the added amount for strengthening the nutrient substances, and does not include the content of nutrient components in other raw materials of milk powder.

[0076] The present invention also provides a method for preparing the above-mentioned special medical purpose formula food, wherein the method comprises: using a wet or dry production process to mix the DHA, ARA and neuraminic acid composition with other raw materials in the special medical purpose formula food to prepare the special medical purpose formula food;

[0077] Preferably, the steps include:

[0078] S01: Mixing: various powder raw materials are added to the powder mixing tank through the air delivery system after being measured according to the formula, and stored to obtain powder raw materials to be vacuum-absorbed; the powder raw materials to be vacuum-absorbed in the powder mixing tank are sucked into the vacuum mixing tank through the vacuum system; the oil specified in the formula is placed in the oiling room according to the formula requirements, and the temperature of the oiling room should be maintained at 50-90°C. After the oil is dissolved, it is pumped into the mixed oil storage tank through the oil pump and flow meter according to the formula ratio requirements to obtain mixed oil; the mixed oil is stored in the oil storage tank at a temperature of 40-50°C and a storage time of 0-12 hours to prevent fat oxidation. According to the formula requirements, the mixed oil is pumped into the mixing tank through the oil pump; calcium powder, minerals, vitamins, etc. are added separately, and 100-200kg of pure water are used to dissolve them separately, and then pumped into the wet mixing tank. After each type is added, 50-150kg of pure water is used to rinse the adding tank and pipeline to obtain a mixed liquid;

[0079] S02: Filtration: The mixed feed liquid is filtered through a filter to remove physical impurities that may be brought into the raw materials, and a filtered feed liquid is obtained;

[0080] S03: Homogenization: The filtered liquid is homogenized by a homogenizer, the first-stage pressure is 105±5bar, and the second-stage pressure is 32±3bar, the fat globules are mechanically treated, and they are dispersed into uniform fat globules to obtain a homogenized liquid;

[0081] S04: Cooling and sterilization: The homogenized liquid enters the plate heat exchanger for cooling: cooled to 5-20°C, temporarily stored in the pre-storage tank, and enters the next process in 0-6 hours. The agitator is turned on according to the set requirements. Double-effect concentration is used during production, the sterilization temperature is ≥83°C, the sterilization time is 25 seconds, and the discharge concentration is 48%-52% dry matter to obtain concentrated milk;

[0082] S05: Concentrated milk storage, preheating filtration, spray drying: The concentrated milk is temporarily stored in the concentrated milk balance tank, preheated to 60-70℃ by the scraper preheater, filtered through a filter with a pore size of 0.5-1.5mm, and then pumped into the drying tower for spray drying by a high-pressure pump. The fine powder is agglomerated at the top of the tower or in the fluidized bed as required. The inlet air temperature is 165-180℃, the exhaust air temperature is 75-90℃, the high-pressure pump pressure is 160-210bar, and the tower negative pressure is -4--2mbar;

[0083] S06: Fluidized bed drying and cooling: The powder coming out of the drying tower is dried twice in a fluidized bed (primary stage), and then cooled to 25-30°C in a fluidized bed (secondary stage). At the same time, human milk oligosaccharide is mixed with a carrier and heated to 60-65°C. Under the action of compressed air, it is evenly dispersed on the surface of the powder. According to the formula requirements, DHA, ARA, nucleotides, and bifidobacteria are weighed and sealed in bags to obtain weighed DHA, ARA, nucleotides, and bifidobacteria;

[0084] S07: Powder screening: Mix the weighed DHA, ARA, nucleotides, bifidobacteria and milk powder in a dry mixer, pass through a vibrating screen to make the particle size of the milk powder uniform, discard the powder residue, collect the powder in a sterilized powder collecting box, and transport it from the powder discharging room to the powder loading room to obtain special medical purpose formula food.

[0085] The present invention also provides a use of the above-mentioned special medical purpose formula food in preparing a product that helps to enhance and / or improve the social behavior of an individual.

[0086] In the above application, preferably, the enhancing and / or improving individual social behavior includes: enhancing the individual's social will and / or social ability;

[0087] More preferably, the social ability includes social interaction ability and / or social adaptability (the ability of an individual to respond and adapt to the social environment and / or social needs around him / her).

[0088] In the above application, preferably, the individual is an infant or a young child.

[0089] According to a specific embodiment of the present invention, the product of the present invention can be a common food or a functional food. More specifically, the food is a snack, a nutritional supplement, a health food or a special medical formula food; the present invention does not make special requirements on the specific form of the product, for example, the snack food can be a milk tablet, candy, etc., and the nutritional supplement, dietary supplement health food or special medical formula food can be in the form of oral liquid, powder, capsule, etc.

[0090] According to a specific embodiment of the present invention, the product of the present invention is a dairy product, such as infant formula, milk powder, milk tablets, cheese, liquid dairy products, complementary foods or nutritional supplements. The product of the present invention is not limited to foods for infants or children, but can also be foods for adults or middle-aged and elderly people.

[0091] It is understandable that for different types of products, the content of each functional substance in the final product should be appropriately adjusted within the range permitted by relevant standards and specifications.

[0092] According to some specific embodiments of the present invention, in the present invention, the product can be any of the aforementioned foods, or a food obtained by further processing using the aforementioned special medical purpose formula food as a raw material, without adding or with adding other substances.

[0093] In the present invention, unless otherwise specified, the infant refers to an infant of 0-12 months old; the toddler refers to a toddler of 1-3 years old.

[0094] This definition applies to all parts of the present invention involving "infants" and "young children" to ensure that the technology, products or methods of the present invention meet the safety standards and applicability for use by infants and young children. The design and use parameters of specific products or equipment can be appropriately adjusted according to the characteristics of different age groups to ensure their safety and effectiveness.

[0095] The present invention has the following beneficial technical effects:

[0096] The present invention provides a method for designing a nutritional composition that helps to enhance and / or improve an individual's social behavior in a special medical purpose formula food, and the special medical purpose formula food has the effect of enhancing and / or improving an individual's social behavior. The composition of DHA, ARA and neuraminic acid contained in the special medical purpose formula food can affect an individual's social behavior, and after combining DHA, ARA and neuraminic acid in a certain proportion, it has a synergistic effect on enhancing and / or improving an individual's social behavior. BRIEF DESCRIPTION OF THE DRAWINGS

[0097] Figure 1 Display the detection results of the convergence frequency of each experimental group.

[0098] Figure 2 Displays the detection results of the approach cumulative time of the experimental examples in each experimental group.

[0099] Figure 3 Displays the test results of the body contact frequency of the experimental examples in each experimental group.

[0100] Figure 4 Displays the test results of the cumulative body contact time of the experimental examples in each experimental group.

[0101] Figure 5 The detection results of the relative movement frequency of the experimental examples in each experimental group are displayed.

[0102] Figure 6 Displays the detection results of the relative movement cumulative time of the experimental examples in each experimental group. DETAILED DESCRIPTION

[0103] In order to have a clearer understanding of the technical features, purposes and beneficial effects of the present invention, the technical solution of the present invention is now described in detail below, but it should not be construed as limiting the applicable scope of the present invention.

[0104] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing the specific embodiments rather than for limiting the scope of protection of the present invention.

[0105] When numerical ranges are given in the embodiments, it should be understood that the two endpoints of each numerical range and any numerical value between the two endpoints can be selected unless otherwise specified in the present invention.

[0106] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.

[0107] In addition to the specific methods, equipment, and materials used in the embodiments, based on the understanding of the prior art by those skilled in the art and the description of the present invention, any methods, equipment, and materials of the prior art that are similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention may also be used to implement the present invention.

[0108] Unless otherwise stated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt conventional techniques in the technical field.

[0109] In each embodiment and experiment, the DHA, ARA and neuraminic acid used are all commercially available food-grade raw materials. Unless otherwise specified, the DHA, ARA and neuraminic acid mentioned in the present invention are measured based on the effective content of the functional components DHA, ARA and neuraminic acid in the raw materials.

[0110] Example 1 A partially hydrolyzed infant milk protein formula food containing a nutritional composition that helps to enhance and / or improve an individual's social behavior (prepared in 1000 kg), wherein the total protein in the partially hydrolyzed infant milk protein formula food includes hydrolyzed milk protein, and the protein with a molecular weight distribution of less than 1000 dal accounts for more than 30% of the total protein:

[0111] 155 kg of hydrolyzed whey protein powder, 270 kg of lactose, 270 kg of solid corn syrup, 90 kg of high oleic sunflower oil, 50 kg of Acer truncatum seed oil, 60 kg of soybean oil, 80 kg of OPO structured fat, 38 kg of complex nutrients, 3 kg of DHA, 7 kg of ARA, 0.1 kg of bifidobacteria, and 0.65 kg of nucleotides.

[0112] The compound nutrients include about 3.0 kg of compound vitamin nutrient package, about 2.0 kg of choline chloride nutrient package, about 12 kg of calcium powder nutrient package, 16 kg of sodium-potassium nutrient package, about 2 kg of mineral nutrient package, and about 3.0 kg of magnesium chloride nutrient package. The base material of each nutrient package is maltodextrin.

[0113] The product contains 13.5g / 100g of protein, 28g / 100g of fat, 54g / 100g of carbohydrates, 100mg / 100g of DHA, 220mg / 100g of ARA, and 400mg / 100g of nervonic acid. The ratio of DHA to ARA is 0.45:1; the ratio of the sum of DHA, ARA and nervonic acid is 0.8:1.

[0114] The preparation process of the partially hydrolyzed infant milk protein formula food containing the nutritional composition that helps to enhance and / or improve the social behavior of an individual is as follows:

[0115] 1) Powder addition: various powder raw materials are measured according to the formula and added to the powder mixing tank through the air delivery system for storage to obtain the powder raw materials to be vacuum-absorbed;

[0116] 2) Vacuum powder suction: The powder materials to be vacuum-absorbed in the powder mixing tank are sucked into the vacuum mixing tank through the vacuum system;

[0117] 3) Melting and oil preparation: put the grease specified in the formula into the oiling room according to the formula requirements. The temperature of the oiling room should be maintained at 70℃. After the oil is dissolved, it is pumped into the mixed oil storage tank through the oil pump and flow meter according to the formula ratio requirements to obtain the mixed oil;

[0118] 4) Storage of mixed oil: The mixed oil is stored in an oil storage tank at a temperature of 45°C for 6 hours to prevent fat oxidation.

[0119] 5) Weighing: Pump the mixed oil into the mixing tank through the oil pump according to the formula requirements.

[0120] 6) Dissolved nutrients and added: Calcium powder, minerals, vitamins, etc. are added separately with 150kg of pure water. After dissolving them separately, they are pumped into the wet mixing tank. After each one is added, rinse the addition tank and pipeline with 150kg of pure water.

[0121] 7) Filtration: The mixed liquid is filtered through a filter to remove physical impurities that may be introduced into the raw materials and obtain a filtered liquid.

[0122] 8) Homogenization: The filtered liquid is homogenized by a homogenizer, the first-stage pressure is 105 bar, and the second-stage pressure is 32 bar. The fat globules are mechanically treated and dispersed into uniform fat globules to obtain a homogenized liquid.

[0123] 9) Cooling and storage: The homogenized liquid enters the plate heat exchanger for cooling: cooled to 15°C, temporarily stored in the pre-storage tank, and enters the next process after 1 hour. The agitator is turned on according to the set requirements.

[0124] 10) Concentration and sterilization: Double-effect concentration is used during production, the sterilization temperature is 85°C, and the sterilization time is 25 seconds. The discharge concentration is 48% dry matter, and concentrated milk is obtained.

[0125] 11) Concentrated milk storage, preheating filtration, spray drying: The concentrated milk is temporarily stored in the concentrated milk balance tank. It is preheated to 65°C by a scraper preheater. After preheating, the material is filtered through a filter with a pore size of 1mm, and then pumped into the drying tower for spray drying by a high-pressure pump. The fine powder is agglomerated at the top of the tower or in the fluidized bed as required. Inlet air temperature: 170°C, exhaust air temperature 80°C, high-pressure pump pressure 190bar, tower negative pressure -3mbar.

[0126] 12) Fluidized bed drying and cooling: The powder coming out of the drying tower is dried again in a fluidized bed (primary) and then cooled to 25°C in a fluidized bed (secondary). At the same time, human milk oligosaccharide is mixed with the carrier and heated to 62°C. Under the action of compressed air, it is evenly dispersed on the surface of the powder, so that the powder particles agglomerate to increase its particle size and solubility.

[0127] 13) Packaging: The flour-making workshop personnel weigh and seal the DHA, ARA, nucleotides, and bifidobacteria in accordance with the formula requirements to obtain the weighed DHA, ARA, nucleotides, and bifidobacteria.

[0128] 14) Dry mixing: Mix the weighed DHA, ARA, nucleotides, bifidobacteria and milk powder in a dry mixer.

[0129] 15) Powder screening: Use a vibrating screen to make the particle size of the milk powder uniform and discard the powder residue.

[0130] 16) Powder output: Collect the powder in a sterilized powder box and transport it from the powder output room to the powder loading room.

[0131] 17) Powdering: Pour the milk powder into the powder storage tank on the large and small packaging machines according to the packaging requirements.

[0132] 18) Packaging: 800g automatic packaging machine nitrogen filling packaging. The oxygen content during nitrogen filling is less than 1%. 900g iron cans automatically filled with nitrogen packaging oxygen content is less than 5%.

[0133] 19) Packing: Put the packaged sachets into cartons and add the powder spoon, then seal with a carton sealing machine.

[0134] 20) Finished product inspection: Sampling inspection is carried out on packaged products according to the inspection plan.

[0135] 21) Storage: Products that have passed the inspection shall be stored in warehouses at room temperature with humidity ≤ 65%.

[0136] The prepared products meet the requirements of relevant standards or specifications.

[0137] Example 2 A partially hydrolyzed infant milk protein formula food containing a nutritional composition that helps to enhance and / or improve an individual's social behavior (prepared in 1000 kg), wherein the total protein in the partially hydrolyzed infant milk protein formula food includes hydrolyzed milk protein, and the protein with a molecular weight distribution of less than 1000 dal accounts for more than 30% of the total protein:

[0138] 160 kg of hydrolyzed whey protein powder, 270 kg of lactose, 270 kg of solid corn syrup, 80 kg of high oleic sunflower oil, 10 kg of Acer truncatum seed oil, 80 kg of soybean oil, 90 kg of OPO structured fat, 38 kg of complex nutrients, 5.5 kg of DHA, 6.5 kg of ARA, 0.1 kg of bifidobacteria, and 0.65 kg of nucleotides.

[0139] The compound nutrients include about 3.0 kg of compound vitamin nutrient package, about 2.0 kg of choline chloride nutrient package, about 12 kg of calcium powder nutrient package, 16 kg of sodium-potassium nutrient package, about 2 kg of mineral nutrient package, and about 3.0 kg of magnesium chloride nutrient package. The base material of each nutrient package is maltodextrin.

[0140] The product contains 14g / 100g of protein, 26g / 100g of fat, 54g / 100g of carbohydrates, 180mg / 100g of DHA, 190mg / 100g of ARA, and 80mg / 100g of nervonic acid. The ratio of DHA to ARA is 0.95:1; the ratio of the sum of DHA, ARA and nervonic acid is 4.6:1.

[0141] The preparation process of the infant milk protein extensively hydrolyzed formula food containing the nutritional composition that helps to enhance and / or improve the social behavior of an individual is the same as that of Example 1.

[0142] The prepared products meet the requirements of relevant standards or specifications.

[0143] Example 3 Infant milk protein deep hydrolyzed formula food containing a nutritional composition that helps to enhance and / or improve individual social behavior (prepared in 1000 kg), the total protein in the infant milk protein deep hydrolyzed formula food includes hydrolyzed milk protein, and the protein with a molecular weight distribution of less than 1000 dal accounts for more than 70% of the total protein:

[0144] 175 kg of hydrolyzed whey protein powder, 500 kg of maltodextrin, 50 kg of soybean oil, 10 kg of Acer truncatum seed oil, 160 kg of medium-chain triglycerides, 50 kg of OPO structured fat, 55 kg of compound nutrients, 6.5 kg of DHA, and 13 kg of ARA.

[0145] The compound nutrients include about 4 kg of compound vitamin nutrient package, about 4 kg of choline chloride nutrient package, about 20 kg of calcium powder nutrient package, 19 kg of sodium-potassium nutrient package, about 4 kg of mineral nutrient package, and about 4 kg of magnesium chloride nutrient package. The base material of each nutrient package is maltodextrin.

[0146] The product contains 15.3g / 100g of protein, 27g / 100g of fat, 50g / 100g of carbohydrates, 200mg / 100g of DHA, 400mg / 100g of ARA, and 80mg / 100g of nervonic acid. The ratio of DHA to ARA is 0.5:1; the ratio of the sum of DHA, ARA and nervonic acid is 7.5:1.

[0147] The preparation process of the infant milk protein extensively hydrolyzed formula food containing the nutritional composition that helps to enhance and / or improve the social behavior of an individual is as follows:

[0148] 1) Powder addition: various powder raw materials are measured according to the formula and added to the powder mixing tank through the air delivery system for storage to obtain the powder raw materials to be vacuum-absorbed;

[0149] 2) Vacuum powder suction: The powder materials to be vacuum-absorbed in the powder mixing tank are sucked into the vacuum mixing tank through the vacuum system;

[0150] 3) Melting and oil preparation: put the grease specified in the formula into the oiling room according to the formula requirements. The temperature of the oiling room should be maintained at 70℃. After the oil is dissolved, it is pumped into the mixed oil storage tank through the oil pump and flow meter according to the formula ratio requirements to obtain the mixed oil;

[0151] 4) Storage of mixed oil: The mixed oil is stored in an oil storage tank at a temperature of 45°C and the storage time is less than 12 hours to prevent fat oxidation.

[0152] 5) Weighing: Pump the mixed oil into the mixing tank through the oil pump according to the formula requirements.

[0153] 6) Dissolved nutrients and added: Calcium powder, minerals, vitamins, etc. are added separately with 150kg of pure water. After dissolving them separately, they are pumped into the wet mixing tank. After each one is added, rinse the addition tank and pipeline with 150kg of pure water.

[0154] 7) Filtration: The mixed liquid is filtered through a filter to remove physical impurities that may be introduced into the raw materials and obtain a filtered liquid.

[0155] 8) Homogenization: The filtered liquid is homogenized by a homogenizer, the first-stage pressure is 105 bar, and the second-stage pressure is 32 bar. The fat globules are mechanically treated and dispersed into uniform fat globules to obtain a homogenized liquid.

[0156] 9) Cooling and storage: The homogenized liquid enters the plate heat exchanger for cooling: cooled to 16°C, temporarily stored in the pre-storage tank, and enters the next process after 1 hour. The agitator is turned on according to the set requirements.

[0157] 10) Concentration and sterilization: Double-effect concentration is used during production, the sterilization temperature is 83°C, and the sterilization time is 25 seconds. The discharge concentration is 50% dry matter, and concentrated milk is obtained.

[0158] 11) Concentrated milk storage, preheating filtration, spray drying: The concentrated milk is temporarily stored in the concentrated milk balance tank. It is preheated to 65°C by a scraper preheater. After preheating, the material is filtered through a filter with a pore size of 1mm, and then pumped into the drying tower for spray drying by a high-pressure pump. The fine powder is agglomerated at the top of the tower or in the fluidized bed as required. Inlet air temperature: 175°C, exhaust air temperature 80°C, high-pressure pump pressure 200bar, tower negative pressure -3mbar.

[0159] 12) Fluidized bed drying and cooling: The powder coming out of the drying tower is dried again in a fluidized bed (primary) and then cooled to 30°C in a fluidized bed (secondary). At the same time, human milk oligosaccharide is mixed with the carrier and heated to 60°C. Under the action of compressed air, it is evenly dispersed on the surface of the powder, so that the powder particles agglomerate to increase its particle size and solubility.

[0160] 13) Packaging: The flour-making workshop personnel weigh and seal the DHA, ARA, nucleotides, and bifidobacteria in accordance with the formula requirements to obtain the weighed DHA, ARA, nucleotides, and bifidobacteria.

[0161] 14) Dry mixing: Mix the weighed DHA, ARA, nucleotides, bifidobacteria and milk powder in a dry mixer.

[0162] 15) Powder screening: Use a vibrating screen to make the particle size of the milk powder uniform and discard the powder residue.

[0163] 16) Powder output: Collect the powder in a sterilized powder box and transport it from the powder output room to the powder loading room.

[0164] 17) Powdering: Pour the milk powder into the powder storage tank on the large and small packaging machines according to the packaging requirements.

[0165] 18) Packaging: 800g automatic packaging machine nitrogen filling packaging. The oxygen content during nitrogen filling is less than 1%. 900g iron cans automatically filled with nitrogen packaging oxygen content is less than 5%.

[0166] 19) Packing: Put the packaged sachets into cartons and add the powder spoon, then seal with a carton sealing machine.

[0167] 20) Finished product inspection: Sampling inspection is carried out on packaged products according to the inspection plan.

[0168] 21) Storage: Products that have passed the inspection shall be stored in warehouses at room temperature with humidity ≤ 65%.

[0169] The prepared products meet the requirements of relevant standards or specifications.

[0170] Example 4 Infant milk protein deep hydrolyzed formula food containing a nutritional composition that helps to enhance and / or improve individual social behavior (prepared in 1000 kg), the total protein in the infant milk protein deep hydrolyzed formula food includes hydrolyzed milk protein, and the protein with a molecular weight distribution of less than 1000 dal accounts for more than 70% of the total protein:

[0171] 175 kg of hydrolyzed whey protein powder, 330 kg of maltodextrin, 210 kg of glucose syrup, 30 kg of Acer truncatum seed oil, 110 kg of soybean oil, 80 kg of medium-chain triglycerides, 30 kg of OPO structured fat, 55 kg of compound nutrients, 3.5 kg of DHA, and 6 kg of ARA.

[0172] The compound nutrients include about 4 kg of compound vitamin nutrient package, about 4 kg of choline chloride nutrient package, about 20 kg of calcium powder nutrient package, 19 kg of sodium-potassium nutrient package, about 4 kg of mineral nutrient package, and about 4 kg of magnesium chloride nutrient package. The base material of each nutrient package is maltodextrin.

[0173] The product contains 15.3g / 100g of protein, 25g / 100g of fat, 54g / 100g of carbohydrates, 120mg / 100g of DHA, 180mg / 100g of ARA, and 240mg / 100g of nervonic acid. The ratio of DHA to ARA is 0.67:1; the ratio of the sum of DHA, ARA and nervonic acid is 1.25:1.

[0174] The preparation process of the infant milk protein extensively hydrolyzed formula food containing the nutritional composition that helps to enhance and / or improve the social behavior of an individual is the same as that of Example 3.

[0175] The prepared products meet the requirements of relevant standards or specifications.

[0176] Experimental study on the efficacy of nutritional composition in improving social ability

[0177] 1. Bee species and grouping

[0178] One-day-old Italian honey bees (Apis mellifera) were used, and the intervention methods of different experimental groups were shown in Table 1 based on the diet of feed honey bees.

[0179] Table 1

[0180]

[0181]

[0182] 2. Basic training of bees

[0183] 2.1 Diet preparation

[0184] Preparation of diet for the control group: weigh 500 g of sucrose and 10 g of casein hydrolysate, dilute to 1 L with ultrapure water, stir to dissolve, filter and sterilize with a 0.22 μm filter membrane to obtain the 50% (w / v) sucrose solution containing 1% (w / v) casein hydrolysate required for the experiment.

[0185] Diet of treatment groups: The free-feeding group added the treatment reagent to the diet of the control group; the single-fed group was fed with a single concentrated reagent in 5 μL sterile sugar water, with each bee receiving a daily diet of 40 μL sugar water.

[0186] 2.2 Bee picking

[0187] (1) Selection of honeycombs

[0188] Honeycomb spleens of appropriate age were selected from the apiary, quickly transported back to the laboratory, and cultured in an incubator (DHP-9162 constant temperature incubator of Zhongyi Guoke (Beijing) Technology Co., Ltd.) at a temperature of 35°C and a humidity of 60-80%.

[0189] (2) Bee picking

[0190] Starting from the second day, observe the status of the emerging bees every day (if they have not emerged, continue to culture them). Gently remove the emerging bees with tweezers and divide them into disposable transparent culture cups, 30 bees per cup. Divide them into enough cups according to the experimental needs.

[0191] 2.3 Bee pretreatment

[0192] (1) Preparation of intestinal fluid

[0193] The fledged bees were taken directly from the apiary, and the intestines were extracted. Each intestine was ground with 100 μL PBS buffer, and then 50% glycerol was added in a 1:1 ratio and stored at -80°C.

[0194] (2) Colonization of intestinal fluid

[0195] Take a sterile 2mL centrifuge tube, add 990μL sterile PBS buffer, add 10μL worker bee intestinal fluid, mix well, and finally use 50% (w / v) sterile sucrose solution to make up to 2mL mark, shake and mix well. Feed each cup of newly emerged bees with 1 tube of the above mixed solution and continue to culture in a constant temperature incubator for 24h.

[0196] 2.4 Treatment and feeding

[0197] After the colonization of intestinal fluid was completed, treatment feeding began. The CV group was fed with the CV diet, and the treatment group was fed with the treatment diet. Treatment feeding continued for 7 days. During this period, the growth status of the bees was observed daily and the diet was changed in time to ensure that the diet was sufficient. The culture conditions were: dark, 35℃, 60%-80% humidity.

[0198] If the animals are gavaged individually, the diet placed in the feeding cup is CV diet, and only different treatment agents are added to the gavage-fed diet.

[0199] 3. Experimental testing

[0200] Social skills test:

[0201] (1) Preparation of the behavioral observation room: Turn on the air conditioner and the exhaust fan of the test bench 1-2 hours before the experiment to keep the temperature of the observation room (26°C) constant and to ensure that there is no odor in the test bench.

[0202] (2) Place the experimental bees in groups of three in a transparent, breathable open field that has been prepared in advance.

[0203] (3) The open field was acclimated on the experimental table for 15 minutes, and the open field was filmed from above for 45 minutes.

[0204] (4) The above videos were analyzed using the Etho Vision XT 17 animal social behavior analysis system to obtain animal social behavior ability data, and social behavior was evaluated from two dimensions: social interaction tendency evaluation and social interaction evaluation.

[0205] 4. Experimental Results

[0206] (1) Results of social interaction tendency evaluation

[0207] The evaluation of social interaction tendency is the frequency and time of experimental animals approaching each other but not engaging in social behavior. The present invention uses approach frequency and cumulative approach time to evaluate the ability to tend to socialize (i.e., reflecting the "social willingness" described in the present invention).

[0208] The approaching frequencies of each experimental case are as follows Figure 1 As shown in the figure, compared with Experimental Example 1, there is no significant difference in the approach frequency of Experimental Example 7; the approach frequencies of Experimental Examples 2 and 3 have an increasing trend, but there is no significant difference; the approach frequency indicators of Experimental Examples 4, 5 and 6 have increased significantly. Compared with Experimental Example 3, Experimental Example 6 has an increasing trend, but it is not significant. Compared with Experimental Example 7, the approach frequency of Experimental Example 6 has increased significantly.

[0209] The cumulative approach time of each experimental case is as follows: Figure 2As shown, compared with Experimental Example 1, there is no significant difference in the approach frequency of Experimental Examples 2-5 and Experimental Example 7, and only the approach cumulative time of Experimental Example 6 is significantly increased; compared with Experimental Examples 3 and Experimental Examples 7, the approach frequency of Experimental Example 6 is significantly increased.

[0210] In summary, in terms of social interaction tendency, at the experimental dose, neuraminic acid intervention alone had no significant effect on approach frequency and cumulative approach time; different proportions of DHA and ARA intervention groups had an effect on approach frequency; combined intervention of DHA, ARA and neuraminic acid significantly increased both approach frequency and cumulative approach time, indicating that the nutritional combination of DHA, ARA and neuraminic acid has an effect on nerve and brain development, promotes social interaction tendency, and has a certain synergistic technical effect on approach frequency and cumulative approach time.

[0211] (2) Social interaction evaluation

[0212] Social interaction evaluation indicates the frequency and duration of actual social interaction of experimental animals. It is the most intuitive expression of an individual's social ability (i.e., reflecting the "social ability" mentioned in the present invention, more specifically mainly including social interaction ability and / or social adaptability). It is evaluated by the frequency of physical contact, the cumulative time of physical contact, the frequency of relative movement, and the cumulative time of relative movement.

[0213] The frequency of physical contact in each experimental case is as follows Figure 3 As shown in Figure 1, there is no significant difference between the groups compared with Experimental Example 1, but there is an increasing trend in Experimental Examples 3, 5, and 6. The cumulative body contact time of each experimental example is shown in Figure 1. Figure 4 As shown, compared with Experimental Example 1, Experimental Example 2, Experimental Example 4, and Experimental Example 5 had no significant differences, and Experimental Example 7 had a significant decrease; Experimental Example 3 had an increasing trend, but no significant difference; Experimental Example 6 had a significant increase in the cumulative time of physical contact. Compared with Experimental Examples 3 and 7, the cumulative time of physical contact in Experimental Example 6 increased significantly.

[0214] The relative movement frequency of each experimental example is as follows Figure 5 As shown in Figure 1, there is no significant difference in Experimental Example 2, Experimental Example 5 and Experimental Example 7 compared with Experimental Example 1; the relative movement frequency of Experimental Example 3, Experimental Example 4 and Experimental Example 6 increased significantly. Compared with Experimental Example 3, Experimental Example 6 has an increasing trend, but it is not significant; compared with Experimental Example 7, the relative movement frequency of Experimental Example 6 increased significantly. The relative movement cumulative time of each experimental example is shown in Figure 1. Figure 6 As shown in the figure, compared with Experimental Example 1, the cumulative relative movement time of Experimental Example 2 and Experimental Example 7 decreased; there was no significant difference between Experimental Example 3, Experimental Example 4 and Experimental Example 5; the cumulative relative movement time of Experimental Example 6 increased significantly. Compared with Experimental Example 3 and Experimental Example 7, the cumulative relative movement time of Experimental Example 6 increased significantly.

[0215] In terms of social interaction indicators, at the experimental dose, intervention with neuraminic acid alone had no significant effect on the frequency of physical contact and the frequency of relative movement, while the cumulative time of physical contact and the cumulative time of relative movement both decreased; intervention groups with different proportions of DHA and ARA had different effects on the frequency of physical contact, the cumulative time of physical contact, the frequency of relative movement and the cumulative time of relative movement, suggesting that the effects of DHA and ARA on social interaction are related to the proportions; after the combined intervention of DHA, ARA and neuraminic acid, the frequency of physical contact, the cumulative time of physical contact, the frequency of relative movement and the cumulative time of relative movement all increased significantly, suggesting that the nutritional combination of DHA, ARA and neuraminic acid has an impact on the development of nerves and brain, and promotes social interaction, and has a certain synergistic technical effect on the social interaction indicators of body contact frequency, cumulative time of body contact, relative movement frequency and cumulative time of relative movement.

[0216] Compared with Experimental Example 1, Experimental Examples 2-5 fortified DHA and ARA in different proportions on the basis of normal diet. The results showed that Experimental Examples 2-5 increased in approach frequency, but only Experimental Examples 4 and 5 had significant differences in increase; there was no significant difference in approach cumulative time in Experimental Examples 2-5, but Experimental Examples 3-5 had an increasing trend; there was no significant difference in body contact frequency and cumulative body contact time in Experimental Examples 2-5, but Experimental Examples 3-5 had an increasing trend; there was no significant difference in relative movement frequency and cumulative relative movement frequency time in Experimental Examples 2, 4 and 5, but the relative movement frequency of Experimental Examples 3-5 had an increasing trend; the cumulative relative movement frequency of Experimental Examples 3 and 5 had an increasing trend. It suggests that different proportions of DHA and ARA have different effects on social behavior. In the experimental examples, the DHA:ARA mass ratio of 1:1 in Experimental Example 3 is the optimal ratio of the two.

[0217] Compared with Experimental Example 1, Experimental Example 7 strengthened neuraminic acid on the basis of a normal diet. The results showed that at the experimental dose and ratio of the present invention, strengthening neuraminic acid alone had no significant effect on the approach frequency, body contact frequency, and relative movement frequency, but could reduce the cumulative approach time, the cumulative body contact time, and the cumulative relative movement time.

[0218] Compared with Experimental Example 1, Experimental Example 6 simultaneously strengthened DHA, ARA and neuraminic acid on the basis of normal diet. The results showed that the intervention in Experimental Example 6 significantly improved social interaction tendency (approach frequency, cumulative approach time) and social interaction (body contact frequency, cumulative body contact time, relative movement frequency and cumulative relative movement time); and compared with Experimental Example 7 in which neuraminic acid was strengthened alone, the approach frequency, cumulative approach time, cumulative body contact time, relative movement frequency and cumulative relative movement time were also significantly increased; compared with the strengthening of DHA and ARA alone, the cumulative approach time, cumulative body contact time and cumulative relative movement time were significantly increased, and the approach frequency, body contact frequency and relative movement frequency all showed an increasing trend.

[0219] According to the above results, the combined intervention of DHA, ARA and neuraminic acid in a specific proportion achieved the optimal nutritional effect on brain nerves and brain functions, and the combined intervention had an increasing effect on approach frequency, cumulative approach time, body contact frequency, cumulative body contact time, relative movement frequency and cumulative relative movement time, indicating that the nutritional combination of DHA, ARA and neuraminic acid has an effect on nerve and brain development, and promotes both social interaction tendency and social interaction, and there is a certain synergistic technical effect.

[0220] The above description of the embodiments is to facilitate the understanding and use of the invention by those skilled in the art. It is obvious that those skilled in the art can easily make various modifications to these embodiments and apply the general principles described herein to other embodiments without creative work. Therefore, the present invention is not limited to the above embodiments, and improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the present invention should be within the scope of protection of the present invention.

Claims

1. A special medical purpose formula food, which contains DHA, ARA and neuraminic acid composition, wherein: The mass ratio of DHA to ARA is 0.2-5:1, and the mass ratio of the total amount of DHA and ARA to neuraminic acid is 0.8-20:1; Among them, based on the dry matter weight of the special medical purpose formula food, the protein content is 10-16g / 100g, the fat content is 21-32g / 100g, and the carbohydrate content is 50-58g / 100g. The special medical purpose formula food is selected from one or more of the following: lactose-free formula or low-lactose formula food for infants, partially hydrolyzed milk protein formula food for infants, deeply hydrolyzed milk protein formula food for infants, amino acid formula food for infants, formula food for premature / low birth weight infants, breast milk nutritional supplements, formula food for infant amino acid metabolism disorders, complete nutrition formula food for food protein allergy, complete nutrition formula food for inflammatory bowel disease, complete nutrition formula food for gastrointestinal absorption disorders, and complete nutrition formula food for abnormal fatty acid metabolism.

2. The special medical purpose formula food according to claim 1, wherein: Calculated by the amount of DHA, ARA and ARA in the neuraminic acid composition, the amount of ARA contained in the special medical purpose formula food is 10-420 mg / 100 g of food dry matter. Preferably, the amount of ARA contained in the special medical purpose formula food is 15-400 mg / 100 g of food dry matter.

3. The special medical purpose formula food according to claim 2, wherein: The special medical purpose formula food is a partially hydrolyzed infant milk protein formula food or an extensively hydrolyzed infant milk protein formula food; the total protein in the partially hydrolyzed infant milk protein formula food includes hydrolyzed milk protein, and the protein with a molecular weight distribution of less than 1000 dal accounts for more than 30% of the total protein, preferably more than 40%; the total protein in the extensively hydrolyzed infant milk protein formula food includes hydrolyzed milk protein, and the protein with a molecular weight distribution of less than 1000 dal accounts for more than 70% of the total protein, preferably more than 80%.

4. The special medical purpose formula food according to claim 3, wherein: Based on 1000 parts by weight of the partially hydrolyzed infant milk protein formula food, the raw materials include: 7 to 50 parts by weight of a compound nutrient comprising calcium powder, vitamins and minerals; 5. The special medical purpose formula food according to claim 3, wherein: Based on 1000 parts by weight of the infant milk protein deep hydrolysis formula food, the raw materials include: 7 to 80 parts by weight of a compound nutrient comprising calcium powder, vitamins and minerals; DHA 2-15 parts by weight; ARA 3-22 parts by weight; Nucleotides 0-1 parts by weight.

6. The special medical purpose formula food according to claim 4 or 5, wherein: The dosage of each component of the composite nutrient containing calcium powder, vitamins and minerals is: Component 1: complex vitamins, wherein each gram of complex vitamins contains: Taurine: 25-340 mg; Vitamin A: 1700~5800μgRE; Vitamin D: 25-70 μg; Vitamin B1: 2000~6800μg; Vitamin B2: 3000~6900μg; Vitamin B6: 1700-4000 μg; Vitamin B 12 : 8~20μg; Vitamin K1: 200-700 μg; Vitamin C: 0-700 mg; Vitamin E: 10-70 mg α-TE; Nicotinamide: 10000~41550μg; Folic acid: 350-920 μg; Biotin: 70-245 μg; Pantothenic acid: 7100-25230 μg; Inositol: 0-250mg; L-Carnitine: 0-60mg; Component 2: Mineral II, wherein each gram of Mineral II contains: Sodium: 40-100 mg; Potassium: 200-500 mg; Component 3: Mineral III, including per gram of Mineral II: Calcium: 200-500 mg; Phosphorus: 75-300 mg; Component 4: Mineral 1, wherein per gram of Mineral 1: Iron: 20-110 mg; Zinc: 23-90 mg; Copper: 2000-4180 μg; Iodine: 500-995 μg; Selenium: 0-200 μg; Manganese: 0-579 μg; Component 5: compound magnesium chloride, wherein per gram of magnesium chloride: magnesium: 80-170 mg; Component 6: Choline chloride, wherein per gram of choline chloride: Choline: 200-950 mg.

7. The method for preparing the special medical purpose formula food according to any one of claims 1 to 6, wherein: The method comprises: using a wet or dry production process to mix the DHA, ARA and neuraminic acid composition with other raw materials in a special medical purpose formula food to prepare the special medical purpose formula food; Preferably, the steps include: S01: Mixing: various powder raw materials are added to the powder mixing tank through the air delivery system after being measured according to the formula, and stored to obtain powder raw materials to be vacuum-absorbed; the powder raw materials to be vacuum-absorbed in the powder mixing tank are sucked into the vacuum mixing tank through the vacuum system; the oil specified in the formula is placed in the oiling room according to the formula requirements, and the temperature of the oiling room should be maintained at 50-90°C. After the oil is dissolved, it is pumped into the mixed oil storage tank through the oil pump and flow meter according to the formula ratio requirements to obtain mixed oil; the mixed oil is stored in the oil storage tank at a temperature of 40-50°C and a storage time of 0-12 hours to prevent fat oxidation. According to the formula requirements, the mixed oil is pumped into the mixing tank through the oil pump; calcium powder, minerals, vitamins, etc. are added separately, and 100-200kg of pure water are used to dissolve them separately, and then pumped into the wet mixing tank. After each type is added, 50-150kg of pure water is used to rinse the adding tank and pipeline to obtain a mixed liquid; S02: Filtration: The mixed feed liquid is filtered through a filter to remove physical impurities in the raw materials to obtain a filtered feed liquid; S03: Homogenization: The filtered liquid is homogenized by a homogenizer, the first-stage pressure is 105±5bar, and the second-stage pressure is 32±3bar, the fat globules are mechanically treated, and they are dispersed into uniform fat globules to obtain a homogenized liquid; S04: Cooling and sterilization: The homogenized liquid enters the plate heat exchanger for cooling: cooled to 5-20°C, temporarily stored in the pre-storage tank, and enters the next process in 0-6 hours. The agitator is turned on according to the set requirements. Double-effect concentration is used during production, the sterilization temperature is ≥83°C, the sterilization time is 25 seconds, and the discharge concentration is 48%-52% dry matter to obtain concentrated milk; S05: Concentrated milk storage, preheating filtration, spray drying: The concentrated milk is temporarily stored in the concentrated milk balance tank, preheated to 60-70℃ by the scraper preheater, filtered through a filter with a pore size of 0.5-1.5mm, and then pumped into the drying tower for spray drying by a high-pressure pump. The fine powder is agglomerated at the top of the tower or in the fluidized bed as required. The inlet air temperature is 165-180℃, the exhaust air temperature is 75-90℃, the high-pressure pump pressure is 160-210bar, and the tower negative pressure is -4 to -2mbar; S06: Fluidized bed drying and cooling: The powder coming out of the drying tower is dried twice in a fluidized bed (primary stage), and then cooled to 25-30°C in a fluidized bed (secondary stage). At the same time, human milk oligosaccharide is mixed with a carrier and heated to 60-65°C. Under the action of compressed air, it is evenly dispersed on the surface of the powder. According to the formula requirements, DHA, ARA, nucleotides, and bifidobacteria are weighed and sealed in bags to obtain weighed DHA, ARA, nucleotides, and bifidobacteria; S07: Powder screening: Mix the weighed DHA, ARA, nucleotides, bifidobacteria and milk powder in a dry mixer, pass through a vibrating screen to make the particle size of the milk powder uniform, discard the powder residue, collect the powder in a sterilized powder collecting box, and transport it from the powder discharging room to the powder loading room to obtain special medical purpose formula food.

8. Use of the special medical purpose formula food according to any one of claims 1 to 6 in the preparation of a product that helps to enhance and / or improve the social behavior of an individual.

9. The use according to claim 8, wherein: The said enhancing and / or improving individual social behavior includes: enhancing individual social willingness and / or social ability; Preferably, the social ability includes social interaction ability and / or social adaptability.

10. The use according to claim 8 or 9, wherein: The individual is an infant or a young child.

Images